← back to search

Noha Abdel‐Wahab

The University of Texas MD Anderson Cancer Center · US
Area of research
Oncology · Genetics
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, CAR-T cell therapy research, and Chronic Lymphocytic Leukemia Research.
h-index
30
citations
4,609
works
116
NIH funding
primary concept
Medicine
email

Recent publications

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Journal for ImmunoTherapy of Cancer 2025cited by 5position: middledoi
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Annals of the Rheumatic Diseases 2023cited by 71position: middledoi
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Journal of Clinical Oncology 2023cited by 65position: middledoi
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
JNCI Journal of the National Cancer Institute 2023cited by 54position: middledoi
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
Cancers 2023cited by 15position: middledoi
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Nature Communications 2022cited by 114position: middledoi
Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis
OncoImmunology 2021cited by 62position: middledoi
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors
Cancer Immunology Immunotherapy 2021cited by 59position: firstdoi
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
OncoImmunology 2021cited by 51position: middledoi
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant
Kidney International 2020cited by 176position: middledoi
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Journal for ImmunoTherapy of Cancer 2020cited by 47position: middledoi
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
Journal for ImmunoTherapy of Cancer 2019cited by 297position: middledoi
Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis
Lupus 2017cited by 148position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Adi Diab · The University of Texas MD Anderson Cancer Center6 papers (2019–2023)Omar Mamlouk · University of Houston5 papers (2019–2023)Ala Abudayyeh · The University of Texas Health Science Center at Houston5 papers (2019–2023)Umut Selamet · Harvard University5 papers (2019–2023)Jamie S. Lin · Royal North Shore Hospital4 papers (2019–2021)Maen Abdelrahim · University of Jordan4 papers (2019–2023)Amanda Tchakarov · University of Houston3 papers (2019–2021)Cassian Yee · The University of Texas MD Anderson Cancer Center3 papers (2019–2021)María E. Suarez‐Almazor · The University of Texas MD Anderson Cancer Center3 papers (2017–2021)William F. Glass · The University of Texas Health Science Center at Houston3 papers (2019–2021) · 2 papers (2019–2021)Ramona Dadu · The University of Texas MD Anderson Cancer Center2 papers (2021–2021)Valda D. Page · The University of Texas Health Science Center at Houston2 papers (2021–2023)Sanjay Shete · The University of Texas MD Anderson Cancer Center1 papers (2021–2021)Cassandra Calabrese · Case Western Reserve University1 papers (2023–2023)Joshua T. Swan · Houston Methodist1 papers (2021–2021)Vickie R. Shannon · Roswell Park Comprehensive Cancer Center1 papers (2021–2021) · 1 papers (2021–2021) · 1 papers (2023–2023) · 1 papers (2023–2023)